Probing peripheral and central cholinergic system responses

Journal of Psychiatry and Neuroscience

Volumn 25, Issue 4, 2000, Pages 325-336

  Naranjo, Claudio A ^a,b   Fourie, Jeanne ^a   Herrmann, Nathan ^a,b   Lanctôt, Krista L ^a,b   Birt, Catherine ^a   Yau, Kenneth K ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aged; Cholinergic agonists; Cholinergic antagonists; Iris; Miosis; Muscarinic agonists; Muscarinic antagonists; Pilocarpine; Scopolamine; Tropicamide

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PILOCARPINE; PLACEBO; SCOPOLAMINE; TROPICAMIDE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIOSIS; PERIPHERAL NERVOUS SYSTEM; PREDICTION; PUPIL REFLEX; PUPILLOMETRY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRIS; MALE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; MYDRIATICS; NEUROPSYCHOLOGICAL TESTS; PILOCARPINE; RECEPTORS, CHOLINERGIC; SCOPOLAMINE; TROPICAMIDE;

EID: 0033758601     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Drachman D, Reisberg B, editors. Alzheimer's disease: the standard reference. New York: The Free Press, 1983. p. 342-3.
2. Muir J, Everitt B, Robbing T. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J Neurosci 1994;14:2313-26.
3. Dunnett S. The role and repair of forebrain cholinergic systems in short-term memory. Studies using the delayed matching-to-position task in rats. Adv Neurol 1993;59:53-65.
4. Squire L, Knowlton B, Musen G. The structure and organization of memory. Ann Rev Psychol 1993;44:453-95.
5. Drachman D, Leavitt J. Human memory and the cholinergic system. Arch Neurol 1974;30:113-21.
6. Bartus R. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: evidence of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978;9:833-6.
7. Davis K, Mohs R, Tinklenberg J, Pfefferbaum A, Hollister L, Kopell B. Physostigmine: improvement of long term memory process in normal humans. Science 1978;201:272-4.
8. Kopelman M, Corn T. Cholinergic "blockade" as a model for cholinergic depletion. Brain 1988;111:1079-110.
9. Vannucchi M, Scali C, Kopf S, Pepeu G, Casamenti F. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience 1997;79:837-46.
10. Araujo D, Lapchak P, Meaney M, Collier B, Quirion R. Effect of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites. J Neurosci 1990;10:3069-78.
11. Aubert I, Rowe W, Meaney M, Gauthier S, Quirion R. Cholinergic markers in aged cognitively impaired Long-Evans rats. Neurosci 1995;67:277-92.
12. Brown J, Taylor P, Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. Toronto: Pergamon Press; 1998. p. 146-51.
13. Mewaldt S, Ghoneim M. The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 1979;10:205-10.
14. Wisniewski K, Wisniewski H, Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-82.
15. Harris W, Goodman R. Hyper-reactivity to atropine in Down's syndrome. N Engl J Med 1968;270:407-10.
16. Sacks B, Smith S. People with Down's syndrome can be distinguished on the basis of cholinergic dysfunction. J Neurol Neurosurg Psychiatry 1989;52:1294-5.
17. Berg J, Gillian-Brandon M, Kriman B. Atropine in mongolism. Lancet 1959;2:441-2.
18. Scinto L, Daffner K, Dressler D, Ransil B, Rentz D, Weintraub S, et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994;266:1051-4.
19. Kardon R. Drop the Alzheimer's drop test. Neurology 1998;50:588-91.
20. Kaneyuki H, Mitsuno S, Nishida T, Yamada M. Enhanced miotic response to topical dilute pilocarpine in patients with Alzheimer's disease. Neurology 1998;50:802-4.
21. Idiaquez J, Alvarez G, Villagra R, Martin R. Cholinergic supersensitivity of the iris in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994;57:1544-5.
22. Katz B, Rimmer S, Klauber M. Cholinergic supersensitivity of the iris sphincter in Alzheimer's disease. Ophthalmology 1988;96:134.
23. Holstein M, Folstein S, McHugh P. "Mini-mental state": A practical method for grading cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-98.
24. Tombaugh T, McIntyre N. The Mini-Mental State Exam: a comprehensive review. J Am Geriatr Soc 1992;40:922-35.
25. Ware J, Sherbourne D. The MOS 36-item shortform health survey (SF-36): conceptual framework and item selection. Med Care 1992;30:473-83.
26. Buschke H. Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 1973;12:543-50.
27. Sunderland T, Tariot P, Weingartner H, Murphy D, Newhouse P, Mueller E. Pharmacological modeling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:599-610.
28. Broks P, Preston G, Traub P, Poppleton P, Ward C, Stahl S. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 1988;26:685-700.
29. Molchan S, Martinez R, Hill J, Weingartner H, Thompson K, Vitiello B. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 1992;17:215-26.
30. Thorndike E, Lorge I. The teacher's: ivord book of 30,000 words. New York: Columbia University Teacher's College Bureau of Publication; 1944.
31. Wechsler D. A manual for the Wechsler adult intelligence scale. New York: Psychological Corporation; 1955.
32. Sellers E, Naranjo C, Giles H, Frecker R, Beeching M. Intravenous diazepam and oral ethanol interaction. Clin Pharmacol Ther 1980;28:638-45.
33. Kaplan HL. Rapid computerized determination of pupil diameter from imperfect video images. Problems of Drug Dependence, 1994, Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II. Rockville (MD): National Institute on Drug Abuse; 1995.
34. Flicker C, Ferris F, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology 1992;107:437-41.
35. Scinto LFM, Wu CK, Firla KM, Daffner KR, Saroff D, Geula C. Focal pathology in the Edinger-Westphal nucleus explains pupillary hypersensitivity in Alzheimer's disease. Acta Neuropathol 1999;97:557-64.
36. Herrmann N, Lanctôt KL. From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can J Psychiatry 1997;42:51S-64S.
37. Francis FT, Cross AJ, Bowen DM, Terry RD, Katsman R, Bick KL, editors. Alzheimer's disease. New York: Raven Press, 1994. p. 247-61.
38. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 1990;27:576-86.
39. Rogers S, Friedhoff L, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.